Comparison Between Results of Trabeculectomy With or Without Anti- Vascular Endothelilal Growth Factor in Patients With Neovascular Glaucoma at Undaan Eye Hospital Surabaya, Indonesia Oral Presentation - Observational Study - General Practitioner
Article Sidebar
-
neovascular glaucoma, secondary glaucoma, trabeculectomy, anti vegf
Abstract
Introduction & Objectives
New intraocular medication, Anti-vascular endothelial growth factor (Anti-VEGF) agents has been
developed in the management of neovascular glaucoma and in glaucoma surgery. But there are no
studies comparing trabeculectomy with Anti-VEGF to no Anti-VEGF treatment in patients with
neovascular glaucoma. This study aims to compare decrease of intraocular pressure (IOP) between
trabeculectomy with Anti-VEGF and without Anti-VEGF in neovascular glaucoma.
Methods
This observational retrospective study comprised 30 medical records of neovascular glaucoma,
divided to 15 medical records of patients with anti-VEGF before trabeculectomy and medical records
of patients operated with trabeculectomy without anti-VEGF, monitored between January 2021 to
December 2021. Patients with incomplete medical records were excluded. Data collected are age,
gender, risk factor, intraocular pressure pre operative, and during 6 months follow-up IOP post
operative. Data analysis uses an Independent T test.
Results
From 30 samples, mean IOP in trabeculectomy with anti-VEGF group generally is 12,26 mmHg.
Meanwhile, mean IOP in trabeculectomy without anti-VEGF group generally is 16,74 mmHg. T
independent test between 2 groups shows that there are significant mean difference between them
during 1-5 months follow-up (1 month: p = 0,022; 2 months: p = 0,007; 3 months: p = 0,007; 4
months: p = 0,042; 5 months: p = 0,029).
Conclusion
Trabeculectomy with prior administration of intravitreal anti-VEGF shows good IOP reduction and
can be implemented in NVG patients.
Full text article
References
Senthil S, Dada T, Das T, Kaushik S, Puthuran GV, Philip R, et al. Neovascular glaucoma - A review. Indian J Ophthalmol [Internet]. 2021 Mar [cited 2023 May 28];69(3). Available from: https://pubmed.ncbi.nlm.nih.gov/33595466/
Bai L, Wang Y, Liu X, Zheng Y, Wang W, He N, et al. The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma. Front Med [Internet]. 2022 Jan 10 [cited 2023 May 31];8. Available from: http://dx.doi.org/10.3389/fmed.2021.766032
Dumbr?veanu L, Cu?nir V, Bobescu D. A review of neovascular glaucoma. Etiopathogenesis and treatment. Romanian journal of ophthalmology [Internet]. 2021 Oct [cited 2023 May 28];65(4). Available from: https://pubmed.ncbi.nlm.nih.gov/35087972/
Rong AJ, Swaminathan SS, Vanner EA, Parrish RK 2nd. Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. Am J Ophthalmol. 2019 Aug;204:62–9.
Rittiphairoj T, Roberti G, Michelessi M. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev. 2023 Apr 3;4(4):CD007920.
Tang Y, Shi Y, Fan Z. The mechanism and therapeutic strategies for neovascular glaucoma secondary to diabetic retinopathy. Front Endocrinol . 2023 Jan 23;14:1102361.
Mannina A, Olivier M, Patrianakos T. Neovascular glaucoma. Dis Mon. 2021 May;67(5):101137.
Havens SJ, Gulati V. Neovascular Glaucoma. Dev Ophthalmol. 2016;55:196.
. Mishra C, Meyer JJ. Neovascular Glaucoma. In: StatPearls [Internet]. StatPearls Publishing; 2022.
Karakteristik klinis glaukoma neovaskular pada penderita retinopati diabetik di pusat mata nasional rumah sakit mata cicendo [Internet]. Perpustakaan Pusat Mata Nasional Rumah Sakit Mata Cicendo. 2017 [cited 2023 May 31]. Available from: https://perpustakaanrsmcicendo.com/2017/07/17/karakteri stik-klinis-glaukoma-neovaskular-pada-penderitaretinopati-diabetik-di-pusat-mata-nasional-rumah-sakitmata-cicendo/
Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, et al. Neovascular glaucoma: a review. International Journal of Retina and Vitreous. 2016 Nov 14;2(1):1–10.
Improving Outcomes in Neovascular Glaucoma. Ophthalmology Glaucoma. 2022 Mar 1;5(2):125–7.
Kim M, Lee C, Payne R, Yue BYJT, Chang JH, Ying H. Angiogenesis in glaucoma filtration surgery and neovascular glaucoma: A review. Surv Ophthalmol. 2015 May 15;60(6):524–35.
Soeprajogo MP. Penggunaan Anti-Vascular Endothelial Growth Factor dalam Terapi Glaukoma Neovaskular [Internet]. 2019 [cited 2023 May 28]. Available from: https://perpustakaanrsmcicendo.com/wpcontent/uploads/2019/04/Penggunaan-Anti-VascularEndothelial-Growth-Factor-dalam-Terapi-GlaukomaNeovaskular.magdalena-purnama-soeprajogo.pdf
Slabaugh M, Salim S. Use of Anti-VEGF Agents in Glaucoma Surgery. J Ophthalmol. 2017 Jun 27;2017:1645269.
Sun Y, Liang Y, Zhou P, Wu H, Hou X, Ren Z, et al. AntiVEGF treatment is the key strategy for neovascular glaucoma management in the short term. BMC Ophthalmol. 2016 Aug 30;16(1):150.
Rayess N, Mruthyunjaya P. Anti-Vascular Endothelial Growth Factor Therapy for Radiation Retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2020 Apr 1;51(4):S44–9.
Xie Z, Liu H, Du M, Zhu M, Tighe S, Chen X, et al. Efficacy of Ahmed Glaucoma Valve Implantation on Neovascular Glaucoma. Int J Med Sci. 2019;16(10):1371.
Arathi SimhaKanza AzizAndrew BraganzaLekha AbrahamPrasanna SamuelKristina B Lindsley. Website [Internet]. 2020 [cited 2023 May 31]. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/146518 58.CD007920.pub3/full
Ryoo NK, Lee EJ, Kim TW. Regression of iris neovascularization after subconjunctival injection of bevacizumab. Korean J Ophthalmol. 2013 Aug;27(4):299303.
Authors
Copyright (c) 2023 Rosalia Adriani Malika, Lydia Nuradianti
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
